SUPER FIBER INC. – Trademark Portfolio

Entity Type: 03

SUPER FIBER INC. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 2 trademarks are registered and 1 is pending. Notable registered marks include BELLWAY. The owner is based in NEW YORK, NY.

500 7TH AVENUE, 8TH FLOOR

NEW YORK, NY 10018

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

BELLWAY
BELLWAY
Registered 2019
BELLWAY
BELLWAY
Registered 2019

Trademark Classifications

SUPER FIBER INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

35
Advertising & Business (1 filing)

Advertising; business management; business administration; office functions

Frequently Asked Questions

How many trademarks does SUPER FIBER INC. have?

SUPER FIBER INC. has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 pending.

What trademark classes does SUPER FIBER INC. file in?

SUPER FIBER INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are SUPER FIBER INC.'s most well-known trademarks?

SUPER FIBER INC.'s registered trademark portfolio includes well-known marks such as BELLWAY. These are among 2 currently registered trademarks in the portfolio.

What is SUPER FIBER INC.'s trademark registration success rate?

SUPER FIBER INC. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 1 application is pending review.